HealthcareMid capRs 14,654 crRs 32.0 cr traded a day
Close on 10 September 2026
818.65
−0.93%
52-week range6% of the way up
792.951,206.00
Market cap
14,654 cr
P/E (TTM)
12.8×
industry 45×
EPS (TTM)
63.95
Revenue YoY
-44.7%
Q1 FY27
Profit YoY
-57.0%
Net margin
28.1%
-8.1pt vs a year ago
Growth trend
-5.2pt
vs last quarter’s YoY
1 month
-10.6%
Below 52w high
47.3%
RSI (14)
19
oversold
Daily swing
2.3%
average true range
Volume
0.5×
vs 20-day average
Traded
Rs 32 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Bottom of the universe
-13.9%
One-year return
Around the median
-5.3%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
-44.7%
Below the 52-week high
from the highest close of the year
-32.1%
1 week
−2.34%
1 month
−10.56%
3 months
−3.42%
6 months
−14.54%
1 year
−5.30%
The read
written from the numbers on this page
The evidence leans negative2 supporting, 6 against, 1 worth knowing
Supporting
matches near a 52-week low, which has beaten the market by +0.38 points over 20 sessions across 48,405 past signals
priced at 13× earnings against an industry median of 45× — 71% below its peers
Against
trading 14% below its 200-day average
at 6% of its 52-week range — nearly everyone who bought in the past year is underwater
down 5% over twelve months
1 of the scans it matches has historically underperformed the market
revenue fell 45% year on year in the quarter ending 30 June 2026
net margin has narrowed from 38.0% to 28.1% across four quarters
Worth knowing
RSI at 19 is washed out — historically the better half of this site's measured edge comes from exactly this condition
What would change this read: a close back above 951, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working
Nothing on this side tonight — not in the filings and not in the price.
Needs watching7
Net profit -57.0% year on year, Rs 480 cr to Rs 206 cr.
-57.0%Rs 480 crRs 206 cr
Revenue -44.7% year on year, Rs 1,329 cr to Rs 735 cr.
-44.7%Rs 1,329 crRs 735 cr
Net margin fell from 36.1% to 28.1%.
36.1%28.1%
Trading 13.9% below its 200-day average.
-13.9%
32% below its 52-week high.
-32%
Only 3.2% above its 52-week low.
+3.2%
A warning rule fires on it tonight: near a 52-week low.
Near a 52-week low
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 1 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
2 of 47 matched on 10 Sep
NATCOPHARM matches 2 of the 47 scans today, across 2 different kinds of evidence.
NATCOPHARM trades at 13× trailing earnings, above its median of 11× over this window — 20% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.11pt vs the market over the next 5 sessions (n=4,339) · M&A filings were typically +0.18pt vs the market over the next 5 sessions (n=1,722) · Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
nothing clear in the filed numbers
Going against it
revenue fell 45% against the same quarter a year earlier
profit dropped 57% year on year
net margin narrowed from 36.4% to 28.1%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
735
186
206
11.53
28.1%
Q4 FY26
31 Mar · consolidated
739
144
269
14.96
36.4%
Q3 FY26
31 Dec · consolidated
647
161
151
8.46
23.4%
Q2 FY26
30 Sep · consolidated
1,363
614
518
28.94
38.0%
Q1 FY26
30 Jun · consolidated
1,329
572
480
26.84
36.1%
Q4 FY25
31 Mar · consolidated
1,221
506
406
22.70
33.3%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-9.8%
Versus 200-day average-13.9%
Below 52-week high-32.1%
Above 52-week low+3.2%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)19.0
Higher closes in last 52 of 5
Six-month return−14.54%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.31%
Volume versus 20-day0.5x
Median daily turnoverRs 32.0 cr
Peers
Healthcare · 68 classified companies
NATCOPHARM trades at 12.8× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — cheaper than them, by 71%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.